Cannabinoid oil compositions may be used to treat central nervous system disorders. An example of the composition is an oral multiparticulate dosage form including a plurality of individual particulates including a solid core with an effective amount of cannabinoid oil bound in microcrystalline cellulose therein and an enteric coating over the solid core.

The invention is directed to a microcapsule and the method to obtain it. The microcapsule comprises a core in the form of a lipid sphere coated by a protein film, wherein the lipid sphere comprises sporulated microorganisms and at least one lipid wall material, and the protein film is a mix of carbohydrate, protein material and water. The method to obtain this microcapsule includes the stages of mixing sphere components, mixing protein film components, homogenizing the protein film and the subsequent coating of the lipid sphere by means of fluidization with the protein film.

The present disclosure relates to orally available stabilized supplement-containing articles (e.g., softgels). The stabilized supplement may be a probiotic, and may contain a stabilizing component derived from chocolate. The present disclosure also relates to methods of making such stabilized articles.

Methods for forming multiphasic microparticles by using wettability engendered template self-assembly (WETS) techniques are provided. A template is used that defines wettable regions to polar and non-polar liquids and non-wettable regions to polar and non-polar liquids. A first liquid is applied to the template and forms a solid or semi-solid release layer. A second liquid is applied over the release layer to form a solid or semi-solid first layer and a third liquid is applied over the first layer to form a solid or semi-solid second layer. The first layer and the second layer can be released from the template by removing the release layer from the template with a treatment agent to form multiphasic microparticles. Methods for making the templates and multiphasic micro particles are also provided.

Methods of making orally available softgels includes pre-wetting a probiotic with an edible oil to produce a wetted supplement, wherein the edible oil is present in a range of 25% to 75% by weight of a total weight of the probiotic and edible oil, heating the wetted supplement to a temperature in a range of 35? C. to 40? C., blending the wetted supplement and a molten chocolate component together to produce a liquid fill material, encapsulating the liquid fill material in a softgel coating to produce an orally available softgel, and cooling the orally available softgel to have a softgel capsule shell comprising 5% to 15% by weight water. The fill material is a solid at room temperature in the cooled orally available softgel.

The present invention is related to baby love male capsules including active ingredients such as fludrocortisone, bumetanide, sodium bicarbonates, sodium chloride, and Licourice extract, inactive ingredients such as gelatin, plasticizers, moisture absorbents, and preservatives. The active ingredients are selected according to ovum wall thickness and cell fragility theories. The present invention leads to a breakthrough in the medical field through which the baby gender can be determined and many chronic diseases can be cured.

The invention relates to a microcapsule comprising at least one active substance selected from lutein and lutein esters embedded in a matrix comprising fish gelatine and optionally one or more other matrix components, wherein the content of said at least one active substance calculated as free lutein is from 0.5 to 25% of total weight of the microcapsule, and which microcapsule does not comprise any added emulsifier. The invention further relates to a process of preparing the microcapsule as well as uses and products comprising the microcapsule.

A method of making an L-menthol dosage form includes forming a wet granulation including an L-menthol source and at least one pharmaceutical excipient. The wet granulation is extruded into an extrudate and the extrudate is cut into individual core pieces. The individual core pieces are spheronized into individual spheronized cores and the individual spheronized cores are dried to form dried individual spheronized cores. The dried individual spheronized cores are spray coated with a liquid proteinaceous material that forms a film of a proteinaceous material over the dried individual spheronized cores. The film of proteinaceous material is dried over the dried individual spheronized cores to form individual subcoated cores. An enteric coating is applied and dried over the individual subcoated cores to form a plurality of individual enteric coated cores.

An oral composition comprising minicapsules wherein the minicapsules comprise one or more therapeutic prophylactic substances in a liquid, semi-liquid, or solid core. The minicapsules have release profiles to release the substance in an active form at one or more sites along the gastro-intestinal tract to maximize absorption and/or therapeutic efficiency.

An oral cyclosporin composition comprises minicapsules having a core containing a cyclosporin, especially cyclosporin A in a solubilized liquid form. The minicapsules have a release profile to release the pre-solubilized cyclosporin, at least in the colon. The composition may be used for treating a range of intestinal diseases.